Company intelligence / Profile preview

DefiniGEN

Cambridge, England, United Kingdom

Ownership: Private
Development stage: Other

Overview

DefiniGEN offers validated in-vitro disease models using human iPSC-derived cells, enabling predictive toxicology and efficacy testing for liver, pancreas, and intestine disease research; data from these models have been published and adopted by major pharma companies

Therapeutic areas: Metabolic DisordersGastroenterology
Modalities: Induced pluripotent stem cell derived therapyCell therapyCRISPR-based therapy
Industry: Non-Drug Biotech

Partnerships

Partnerships with several top 10 global pharmaceutical companies and CROs

Beyond the preview

Go deeper on DefiniGEN.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DefiniGEN.

Explore the full profile